Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

NCT05267106 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
83
Enrollment
INDUSTRY
Sponsor class

Stopped Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.

Conditions

Interventions

Sponsor

Incyte Corporation